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Sllmmal-y 
In an attempt to identify a molecule in target recognition by CD3- large granular lymphocytes 
(LGL), we have generated a rabbit antiidiotypic (anti-ID) serum against a monoclonal antibody 
(mAb 36) that reacted with the cell membrane of K562. Flow cytometry analysis demonstrated 
that the anti-ID serum bound selectively to CD3- LGL and that F(ab')2 fragments of the anti- 
ID serum blocked both target cell binding and lysis by NK cells. Stimulation of CD3-  LGL 
with F(ab')z fragments resulted in the release of serine esterases and the secretion of interferon % 
Furthermore,  anti-ID  F(ab')2 antibodies  crosslinked  to  anti-DNP  F(ab')2 mediated directed 
cytotoxicity of a non-natural killer (NK)-susceptible mouse target (YAC-1) via this surface ligand. 
These functional reactivities were only removed by adsorption with the specific idiotype. Protein 
analysis showed that the anti-ID serum immunoprecipitated 80-,  110-, and 150-kD proteins. 
Using this anti-ID, a partial cDNA was cloned and an antipeptide  antiserum was made against 
the portion of the predicted amino acid sequence that corresponded to a portion of the ID binding 
region. This antipeptide serum exhibited similar functional and biochemical reactivities to those 
observed with the anti-ID serum.  These data suggest that the cell surface moiety recognized 
by the anti-ID and anti-p104 is novel and is selectively involved in both recognition and triggering 
of NK-mediated lytic function. 
N 
'K activity has been hypothesized as the first line of de- 
fense against spontaneously developing tumor cells and 
many microorganisms (1-5). In mice, rats, and humans, this 
cytotoxic activity is mediated predominately by CD3- LGL 
(6-9). This lymphocyte subset also demonstrates  antibody- 
dependent cellular cytotoxicity (ADCC) 1 (2) and has the ca- 
pacity to secrete lymphokines that augment or suppress cell- 
mediated immunity (5, 10, 11). In addition, LGL secrete  IFN-3/ 
in response to the interaction of CD3- LGL with NK target 
x Abbreviations  used  in  this paper:  ADCC,  antibody-dependent  cellular 
cytotoxicity; anti-ID, antiidiotypic; BBS, borate-buffered saline; DTNB, 
dithiobis (2-nitrobenzoic acid); KLH, keyhole limpet hemocyanin;  NRS, 
normal  rat  serum;  SMC,  succinimidyd  trans-4-(N-maleimidyl-mathyl) 
cyclohexane-l-carboxylate. 
cells, presumably through triggering of appropriate recogni- 
tion receptors (6). 
A model has recently been proposed that defines the mech- 
anism of cytotoxicity by LGL in two dearly distinguishable 
steps (12). The first step is recognition and binding of the 
LGL to the target cells (6, 12-14), while the second step in- 
cludes post-binding events that lead to lysis of the target cell. 
Studies have shown that target recognition by CD3-  LGL 
does not involve the TCR and that CD3-  LGL lack gene 
rearrangement and expression of the c~,/3, and 3' chains of 
the TCP, (6, 13-18). Furthermore, target recognition is not 
mediated via the Fc receptor that functions in LGL-mediated 
ADCC killing (12). Thus, the mechanisms of target cell rec- 
ognition and triggering of lysis by LGL remain unclear. 
In the present study, an antiidiotypic (anti-ID) antiserum 
directed against a mAb (mAb 36) (Bino, T., J. Rossio, J. L. 
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blocked the binding and lysis of CD3-  LGL to NK-suscep- 
tible target cells was generated in rabbits. This anti-ID an- 
tiserum was shown to react with human LGL and to speci- 
fically inhibit the LGbmediated binding and lysis of tumor 
targets. Moveover, the anti-ID antiserum activated the lytic 
mechanism of LGL based on its ability to mediate redirected 
lysis of NK-resistant targets. Furthermore, pretreatment of 
LGL with the anti-ID antiserum perturbed the membrane 
of the LGL and triggered the release of serine esterases  and 
IFN-3,.  This anti-ID antiserum has been used to isolate a 
novel partial cDNA clone from a human NK cDNA X-gt11 
expression library (Anderson, S. K., S. Gallinger, R. Roder, 
J. L. Frey, H. Young, andJ. g. Ortaldo, manuscript in prep- 
aration). Based on the predicted protein sequence of  the cDNA, 
a synthetic peptide (p104) was made with an amino acid se- 
quence that corresponded to a portion of the idiotype binding 
region of this gene. The anti-p104 serum reacted with LGL 
and demonstrated functional properties in a manner similar 
to that of the anti-ID antiserum. Although other cell surface 
structures may exist on CD3-  LGL that  also  may be in- 
volved in the binding of NK cells to NK-susceptible targets, 
the surface  moiety we have described appears to be a very 
important structure in the recognition and lysis of tumor 
targets by NK cells. 
Materiah  and Methods 
Cell Lines and Antibodies.  K562, derived from a patient with 
chronic myelogenous leukemia in blast crisis (19); MOLT-4, a T 
lymphoid cell line derived from a patient with acute lymphocytic 
leukemia (20); and FeMX, a melanoma call line (6), were cultured 
in RPMI 1640 (BioFluids, Inc., R_ockville,  MD) supplemented with 
10%  heat-inactivated FCS (Biofluids, Inc.),  100 #g/ml of gen- 
tamicin, and 0.6 ng/ml of r-glutamine  (Biofluids, Inc.). 
Source and Preparation of Human PBL.  Leukocytes  were sepa- 
rated from huffy coats of peripheral blood by centrifugation  on 
FicoU-Hypaque  gradients. Human LGL and T ceUs were prepared 
as previously  described  (21, 22). Monocytes  were isolated  from plastic 
dishes and thoroughly washed with PBS, and collected by treat- 
ment of the plastic dishes with Versene solution (Bethesda Research 
Laboratories, Gaithersburg, MD) and scraping. LGL-emiched  prepa- 
rations contained 80-90% LGL as determined by morphological 
analysis of Giemsa-stained cytocentrifuge preparations, and were 
70-75%  CD11  +,  75-80%  CD16 +,  and <5%  CD3 § as deter- 
mined by flow cytometry. Purified T cell preparations contained 
<1% LGL and were >95%  CD3 +.  The ceils were cultured  in 
RPMI 1640 supplemented with 10% human  AB serum (M. A. 
Bioproducts, Walkersville, MD), 0.1 mM nonessential amino acid, 
2 mM sodium pyruvate, 4 mM L-glutamine, 50 #g/ml gentamicin 
and 2.5  x  10 -s mM 2-ME (Bio-Rad Laboratories, Richmond, 
CA). Rat LGL and T cells were also obtained from peripheral blood 
and prepared as previously described (23). 
Preparation of Rabh't Anti-ID Antibody.  Three rabbits were ini- 
tially immunized with a subcutaneous injection of an emulsion of 
0.5 ml of 100/~g of affinity-purified mAb 36 (IgM) mixed with 
an equal volume of CFA. After 14 d, another subcutaneous injec- 
tion of 100 ~tg mAb 36 mixed with an equal volume of IFA was 
administered. 7 d later, the rabbits were bled, and the serum was 
prepared. Antiisotype antibody was removed from the serum using 
a control mouse IgM, MOPC 104E (Litton Bionetics, Charleston, 
SC) Sepharose 4B IgM affinity column. Nonbound eluted material 
was partially purified by precipitation with 35% ammonium sul- 
fate and an ELISA for anti-ID antibody was performed on micro- 
titer plates that had been coated with mAb 36 or with MOPC 
104E. Positive  results on mAb 36 plates with parallel  negative results 
on MOPC 104E confirmed the presence of the anti-ID antibody. 
Prebleed normal rabbit serum (NRS), purified by the same proce- 
dure as described above, was used as a control in all experiments. 
For flow cytometry studies, the anti-ID  antibody was affinity 
purified from serum using a mAb 36 Sepharose-4B  column. Anti- 
ID antibodies were eluted with 3.5 M MgClz and then dialyzed 
against PBS. 
Preparation of Rabbit Antipeptide Antiserum.  Peptide 104 (Syn- 
thesized by Bio-Synthesis, Inc., Denton, TX) was conjugated to 
keyhole limpet hemocyanin (KLH) using difluorodinitrobenzine 
(24). A rabbit was given a primary injection consisting of 100/~g 
p104-KLH mixed with an equal volume of CFA. Every 2 wk for 
2 mo, animals were boosted with 100/~g p104-KLH plus an equal 
volume of IFA. Test bleeds were analyzed for specific antibody to 
p104 using an ELISA. 
Preparation of Anti-ID  F(at/)z Fragments.  IgG was  partially 
purified from anti-ID rabbit serum and NRS by ammonium sul- 
fate precipitation. The IgG fractions were diluted 1:1 with 0.1 M 
phosphate buffer, pH 8, and passed through protein A-Sepharose 
CD4B columns (Pharmacia Fine Chemicals, Piscataway, NJ). The 
columns were washed with 0.1 M phosphate buffer, pH 7.5, and 
the adsorbed antibody was eluted with 1 M acetic acid. The pH 
of the eluate was adjusted to 4.2 with 1 N NaOH, a solution of 
pepsin (1 mg pepsin/30 mg antibody) in 0.1 M acetate buffer pH 
4.2 was added, and the mixture was incubated at 37~  for 16 h. 
The digestion was terminated by adjusting the pH of the solution 
to 7.6 with 1 N NaOH. Purification of F(ab')2 fragments was ac- 
complished by passage over a protein A-Sepharose CD4B column. 
The F(ab')2 fragments were dialyzed against PBS, and no detect- 
able intact IgG was observed  when assessed by SDS-PAGE analysis. 
Preparation of Heterocross-linked Antibodies.  F(ab')2  fragments of 
either  NRS (prebleed) or rabbit  anti-ID  were crosslinked with 
F(ab')2 fragments of rabbit anti-DNP (25-27). Briefly, a fourfold 
molar excess of Succinimidyl-3-(2-Pyridyldithiol) propionate was 
added to either anti-ID  F(ab')z (10 mg/ml) or NRS F(ab')2 (25 
mg/ml) in borate-buffered saline, pH 8.5 (BBS). Similarly, a three- 
fold molar excess of Succinimidyl trans-4-(N-maleimidyl-mathyl) 
Cyclohexane-l-carboxylate (SMCC) was added to the rabbit anti- 
DNP F(ab')z (6 mg/ml) in BBS. After 30 rain at room tempera- 
ture, the anti-ID and NRS were brought to pH 4.5 and reduced, 
as described. These proteins then were passed through a Sepharose 
PD10 column in 0.1 M PO4, 0.1 M NaC1, pH 7.5, and added to 
the SMCC-derivatized anti-DNP F(ab')2. After induction for 4 h 
at 37~  the heterocross-linked proteins were fractionated on a 1.6 
x  90-cm vitragel AcA 34 column. Peaks containing F(ab')2 (>100 
kD) were pooled and concentrated. The crosslinked material was 
predominantly  150 kD in molecttlar mass (one anti-ID  or NRS 
F[ab']2 crosslinked to one anti-DNP F[ab]z), as  determined  by 
SDS-PAGE. These crosslinked antisera were used to test for induc- 
tion of  cytotoxicity with targets that had been chemically  modified 
by treatment  with 1 M trinitrobenzoylsulfonate  (25). 
Binding Assay.  The binding  assay was performed by incuba- 
tion of 100/~1 of LGL (10  + cells/ml) with F(ab')a fragments of 
NRS or anti-ID for 15 min at 22~  followed by the addition of 
100/~1 of target cells (10  + cells/ml), and centrifugation  at 120 g 
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ting, and the percent of lymphocytes bound to target cells was de- 
termined  by counting at least 200 lymphocytes in suspension. 
Cytotoxicity Assay.  Cytotoxicity assays were performed using 
a StCr release assay as previously described (28). For experiments 
involving pretreatment  of effector cells, 2  x  10  + LGL/ml were in- 
cubated for 18 h at 37~  with various doses of whole antiserum, 
F(ab')2 fragments or IL2 (C,  etus Corp., Emeryvilh, CA) and then 
washed before performing  the 4-h StCr release assay. In each ex- 
periment,  a control was included using cells incubated in media 
alone. Three replicates were used for each experimental group, and 
the percent-specific lysis was calculated as: 100x  [(total cpm in ex- 
perimental wells)  -  (cpm in wells with target cells alone)/(total 
cpm incorporated into target cells)]. The percent control lysis was 
calculated as: 100x  (percent experiment/percent  control). 
BLT Esterase Assay.  BLT esterase activity was estimated using 
a microtiter  assay (29). Briefly, 50/zl of sample was added to 100 
/~1 of 1 mM dithiobis  (2-nitrobenzoic  acid) (DTNB) made up in 
PBS containing  1 mM CaC12 and  1 mM MgC12, pH 7.2.  The 
reaction was initiated by adding 50 #1 of 0.5 mM Nc~-CBZ-t-Lys- 
thiobenzyl ester (BLT; Sigma Chemical Co., St. Louis, MO). The 
duration  of the assay varied depending  upon the length of time 
necessary for optimal  color development.  The  rate  of increase 
of absorbance at 410 nm was measured on a microplate  reader 
(MR5000; Dynatech Corp., Alexandria, +CA). Controls of sample 
and DTNB or DTNB and BLT were always performed to exclude 
nonspecific activities. 
IFN-'y Assay.  RIA of human IFN-3, (Centocor, Malvern, PA) 
was performed with culture supernatants obtained after treatment 
of 2  x  106 LGL/ml as described above. 
Radiolabeling of Proteins.  Intact  CD3-  LGL,  T  cells, and 
monocytes  were surface labeled with t2sI using  lactoperoxidase, 
which selectively  labels only surface proteins (30). Briefly, 2  x  107 
cells were washed and resuspended in 100/~1 PBS. 1 mCi mI (16 
mCi//zg;  Amersham  Corp.,  Arlington  Heights,  IL) was added, 
followed by 50 #1 of lactoperoxidase (2 mg/ml PBS; Sigma Chem- 
ical Co.),  and 20 #1 0.03% H202 in PBS at 25"C. After 5 min 
of incubation,  50/xl of lactoperoxidase and 20/~1 of 0.03% H202 
were added, and the mixture  was incubated for another  5 min at 
25~  The reaction was terminated by adding 200/~1 of 10 -2 M 
potassium iodide in PBS. After extensive washing with PBS, the 
cells were lysed in 0.05 M Tris-HC1, pH 7.6, buffer containing 
0.2 M NaC1, 0.005 M EDTA, 0.1 mM PMSF, 10 mM iodoaceta- 
mide, 1/zg/ml antipain, 1/~g/ml chymostatin,  1/~g/ml pepstatin, 
1/~g/ml leupeptin,  and 1% Triton X-100 (Sigma Chemical Co.). 
Proteins were immunoprecipitated  from cell lysates with partially 
purified anti-ID  serum or NRS, and protein A-Sepharose Cb4B. 
Immunoprecipitates  were washed extensively with 0.05 M Tris- 
HC1, pH 7.6, 0.25 M NaC1, and 0.005 M EDTA, and 0.1% Triton 
X-100. Samples were analyzed by SDS-PAGE on 7.5% acrylamide 
gels (31). 
Metabolic Labeling of Proteins.  CD3- LGL were metabolically 
labeled with 3SS-methionine (Amersham Corp.) as previously de- 
scribed (32). The labeled cells were lysed and proteins immunopre- 
cipitated  as described above. 
Flow Cytometry.  5  x  106 LGL in 50 #1HBSS containing 0.1% 
BSA and 0.1%  NuNs were incubated for 30 rain at 4~  with 5 
/~g/ml of anti-ID, anti-p104, or NR.S. The cells then were washed 
twice with the same solution and labeled with a FITC-conjugated 
F(ab')z  fragment  of  goat  anti-rabbit  IgG  antiserum  (Cappel 
Laboratories, West Chester, PA). In addition, binding of anti-CD3, 
anti-CD16,  and CD56 (Leu19: Becton Dickinson  & Co., Moun- 
tain View, CA) directly labeled with PE was analyzed using flow 
cytometry. Data were analyzed using FACScan  |  flow cytometer 
(Becton Dickinson  & Co.). 
Results 
Iden~f~ation of lmmunoreactive Lymphocyte Subsets.  To define 
the cell populations(s)  that  express the molecule to which 
the anti-ID and anti-pl04 antisera react, two-color flow cytom- 
etry analysis  was performed on PBL using anti-CD56-PE, 
anti-CD16-PE,  anti-CD3-PE,  NRS-FITC,  F(ab')z anti-ID- 
FITC, and anti-pl04-FITC.  Fig.  1 denotes the results typi- 
cally seen (representative of >25 donors) with various popu- 
lations of lymphocytes. As shown in Fig.  1 B, panels I-3, 
using LGLenriched lymphocytes (50%), most CD56 + lym- 
phocytes bound the anti-ID and, with less intensity,  to the 
anti-p104 antibodies (panels 2 and 3). Panel 4 shows that all 
of the CD16 + cells also exhibited reactivity with the anti- 
ID  antibodies.  In contrast,  CD3 + lymphocytes  in  a  total 
PBL population did not react with the anti-ID or anti-p104 
antisera  (panels 5  and 6).  However, in most donors,  there 
was a small population of CD3-, CD56 + calls (both bright 
and dim staining) that did not react with the anti-ID or with 
the anti-p104. The anti-ID and anti-p104 did not react with 
human monocytes (representative of the cells found in quad- 
rant 3 of panel 5), fresh rat LGL, or human or rat T  cells, 
and also did not react with  the NK target cells,  MOLT-4 
and K562 (data not shown). These results suggested that the 
molecule to which the anti-ID and the anti-p104 bound was 
unique  to human  CD3-  LGL. 
Inhibition of Binding.  Since the anti-ID antiserum bound 
to LGL, experiments were performed to determine whether 
this antiserum would block the binding of the LGL effectors 
to the tumor target cell.  Inhibition of binding would sug- 
gest that the antigen(s) recognized by the antibody were in- 
volved in LGbmediated target recognition. This hypothesis 
was tested by measuring the ability of F(ab')2 fragments of 
anti-ID  or  NRS  to  inhibit  binding  of LGL  to  the  NK- 
susceptible target cells K562 and MOLT-4. Since both LGL 
and K562 cells express Fc receptors, F(ab')2 fragments of the 
anti-ID were necessary to avoid the possibility of nonspecific 
or Fc receptor-mediated reactions. When CD3-  LGL were 
incubated with F(ab')z fragments of the anti-ID antiserum, 
a dose-dependent inhibition of conjugate formation between 
the LGL effectors and K562 or MOLT-4 target cells was ob- 
served (Table 1). A 1-/~g dose of anti-ID inhibited the binding 
of LGL to K562 or MOLT-4 cells by 60% and 52%, respec- 
tively. These data suggested that the structure recognized by 
the anti-ID antiserum plays a role in the interaction between 
LGL and their  target ceils. 
Specificity of the Anti-ID Antiserum.  LGL are known to 
exhibit at least two mechanisms for cytotoxic activity. One 
lyric mechanism, ADCC, is mediated through the Fc receptor. 
However, the Fc receptor is not involved in NK cell-medi- 
ated lysis of tumor targets. If the anti-ID antiserum is recog- 
nizing  a  functionally  important  receptor  involved  in  the 
antibody-independent lysis of tumor targets, it should be pos- 
sible to inhibit NK cell-mediated lysis, but not ADCC, with 
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Figure  1.  (.4) The predicted  amino acid sequence  for the idiotype binding region (bo/d type) and the peptide sequence used in generating anti-pl04 
antisera (underlined). (B) Two-color flow cytometry studies,  low density lymphocytes containing 50%  CD3-CD56 + and 50%  CD3+CD56 -  (panels 
I-4) or B cell-depleted lymphocytes containing 80%  CD3*CD56 -  and 20%  CD3-CD56 + cells  (panels 5 and 6) were analyzed  directly for their 
two-color expression of the rabbit anti-ID and lymphocyte markers. (Panel I) CD56/PE  x  NRS/FITC;  (panel 2) CD56/PE  x  anti-ID/FITC; (panel 
3) CD56/PE  x  anti-pl04/FITC;  (panel 4) CDI6/PE  x  anti-ID/FITC; (panel 5) CD3/PE  x  anti-ID/FITC; (panel 6) CD3/PE  x  anti-pl04/FITC. 
Quadrant  I  (orange  only); 2  (double positive), 3  (negative);  and 4  (green  only). 
this antiserum. Therefore, the anti-ID antiserum was tested 
for its ability to inhibit the binding of the same LGL effector 
cells to the NK-resistant  cell line (FeMX) that had been coated 
with rabbit antibody. Under these experimental conditions, 
the anti-ID  did not block conjugate  formation  (Table I). 
Since the anti-ID  serum was found to inhibit  antibody- 
independent binding of LGL to tumor cells,  but not LGL- 
mediated antibody-dependent  binding,  we examined the ability 
of the  anti-ID  antiserum  to  inhibit  NK  activity  vs.  NK- 
mediated  ADCC  activity.  The  direct  incubation  of  the 
F(ab')2 fragments of the anti-ID with CD3-  LGL and K562 
target cells resulted in a dose-dependent inhibition of target 
cell tysis as measured  by SlCr release,  with 50%  inhibition 
of cytotoxicity occurring at a dose of 20/zg/ml  of anti-ID 
(Fig.  2 A).  Higher doses of anti-ID  (/>80/zg/ml)  resulted 
in complete inhibition of cytolytic activity in four of five donors 
tested. Control F(ab')2 fragments of NRS, analyzed  at these 
same concentrations, did not inhibit NK-mediated lysis. Similar 
results were observed when MOLT-4 cells were used as the 
targets (data not shown). Thus, the anti-ID sdectively blocked 
NK activity and did not inhibit the FcR-dependent binding 
(Table 1) and lysis (Fig. 2 A) by CD3-  LGL. In parallel ex- 
periments, other control antibodies that were reactive with 
adhesion  molecules  such as CDlla  and  ICAM  lacked  this 
specificity  and  blocked  both  forms  of cytolysis  (data  not 
shown). Therefore, these data collectively demonstrate that 
the anti-ID can selectively inhibit the NK activity (both its 
ability to bind and kill) of a single effector cell population 
that also mediates ADCC. These data supported the hypothesis 
that the anti-ID  was reacting with a cell surface molecule 
involved in NK-mediated  lysis. 
Because the rabbit  antiserum  contains antiallotype  anti- 
bodies in addition to the anti-ID, it was critical  to demon- 
strate  that the active antibody in the rabbit  antiserum was 
the anti-ID.  Therefore, experiments were performed to ex- 
amine the effects of anti-ID adsorption on antiserum binding 
(Table 1) and lysis (Fig. 2 B). When antiserum was depleted 
of anti-ID reactivity by mAb 36, an IgMr, it no longer in- 
hibited LGL-mediated  binding (Table  1) nor lysis  of target 
cells (Fig. 2 B). Parallel adsorption of the anti-ID with irrele- 
vant control mAbs (an IgMX and an IgMr) did not remove 
these  inhibiting  activities.  Treatment  with  control  F(ab')2 
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Percent  inhibition 
Percent 
Targets  Conjugates*  #gS  NRS  anti-ID 
Absorbed with:* 
ID  MOPC  mAb35 
(IgM[K])  (IgM[)~])  (IgM[K]) 
_+ SE 
K562  59  +  2 
MOLT-4  34  +  3 
FeMX  (ADCC)  ~  55  +  4 
0.1  1  22 II  2  211P  24 PI 
1  3  6011  2  6111  64II 
5  19 II  75 II  10  7711  7511 
0.1  0  15 II  1  1711  16 n 
1  5  52 II  3  5111  5411 
0.1  0  0  ND  ND  ND 
1.0  1  2  ND  ND  ND 
5.0  2  1  ND  ND  ND 
* Percent  conjugates without antibodies (see Materials and Methods). 
* Anti-ID sera adsorbed with Sepharose-4B-bound antibody. This loss of reactivity was seen with four (of four)  affinity absorptions. 
S Refers  to the micrograms  of F(ab')2 NRS or anti-ID used to inhibit conjugate  formation. 
II Significant inhibition at p <  0.05  (Student's  T-test) compared  to conjugates  formed in the absence of antibodies. 
'1 FeMX was coated with a rabbit antimelanoma serum and used as an ADCC target.  FeMX is not susceptible to NK-mediated lysis and does not 
form conjugates  with LGL in the absence of antibody. 
fragments of NRS at the same dose also did not significantly 
inhibit  conjugate formation. 
Evidence that the Anti-ID Recognizes a Triggering  Moiety.  Pre- 
vious studies have demonstrated that heterocross-linked an- 
tibodies containing one antibody against a receptor on the 
cytotoxic cell crosslinked to a second antibody that  recog- 
nizes a target cell surface component can induce cytotoxic 
cells to lyse otherwise NK-resistant target cells. These studies 
have demonstrated that only triggering surface receptors like 
the TCR (CD3) and Fcy receptors (CD16) on K/NK cells 
and monocytes are capable of inducing  this redirected lysis 
(33). To determine whether the structure bound by the anti- 
ID was capable of promoting target cell lysis, anti-ID F(ab')2 
crosslinked  with  rabbit  anti-DNP  F(ab')2  was  added  to 
CD3-  LGL in the presence of DNP-modified YAC-1 mouse 
target cells that are resistent to lysis by human LGL. When 
the DNP-treated YAC-1 cells were exposed to the heterocross- 
linked  antibodies  on  the  CD3-  LGL,  lysis  of the  YAC-1 
cells was observed (Fig. 3 A).  In contrast,  cytotoxicity was 
not observed when either non-DNP-modified YAC-1 targets 
or heterocross-linked anti-DNP F(ab')2  x  NRS F(ab')2 were 
used. The heterocross-linked antibody alone was not cyto- 
toxic against YAC-1. Since YAC-1 mouse target cells are resis- 
tant to lysis by human LGL, intact rabbit (Ig) anti-DNP was 
used as a positive control for ADCC  activity (Fig.  3 A). 
Induction of the LGL lytic mechanism can be monitored 
by the ability of an antibody against a triggering  molecule 
to mediate reverse ADCC (6). When LGL were pretreated 
with either anti-ID or anti-p104 antisera before incubation 
with an FcR-positive NK-resistant Raji target, both antisera 
mediated reverse ADCC in a dose-dependent manner with 
the maximum lysis being 32% and 36% for the anti-ID and 
the anti-p104,  respectively (Fig.  3 B). The maximum level 
of lysis obtained with NRS was 7%. Therefore, these results 
further supported the hypothesis that the anti-ID recognized 
a functional cytotoxicity-triggering molecule on the surface 
of LGL. 
It has been reported elsewhere that both NK cells and T 
cells release serine esterases in response to perturbation of mem- 
brane receptors (34, 35). The data presented in Table 2 illus- 
trate that  incubation of LGL with  F(ab')2 fragments of ei- 
ther anti-ID or anti-p104 elicited LGL to release 10 and 42 U 
of BLT esterase,  respectively (representative of three experi- 
ments). This level of activation by the anti-ID and anti-p104 
was higher than the 2.0 U  of BLT esterase observed for the 
positive control (LGL and K562 tumor target cells).  In fact, 
the anti-pl04-induced activation exceeded even the ADCC- 
positive control (20 U). However, the BLT esterase release 
induced by the normal rabbit serum did not exceed that in- 
duced by the negative controls, medium alone, or the stimu- 
lation of LGL with uncoated Raji cells. These data demon- 
strated that both antibodies were able to trigger serine esterase 
release in LGL in response to the interaction of the antibodies 
with  their  target  cell ligand. 
Another consequence of stimulating LGL with target cells 
or with Ib2 is the induction of IFN-3" secretion (6, 36). There- 
fore, if the anti-ID or anti-p104 antisera were reacting with 
a tumor recognition molecule, then treatment of LGL with 
these antisera might be expected to stimulate LGL to secrete 
IFN-'y. LGL were incubated with different doses of F(ab')2 
1531  Frey et al. 120 
100 
|  s. 
0 
5.5 
.  .  ,,I  ,  ,  ,  ,  ,  ,,1  ,  i  a  ''~'_  ￿9 
1  10  150 
Antibody  Added  (uglml) 
5o 
er  45 
r 
m 
55 
"~  ,,e 
,.J 
~  z2 
15  '  '  ~  ' 
0.525  1.2s  t.5  5.o 
Antibody  Added  (uglwell) 
Figure 2.  Specificity  of anti-ID reactivity. (A) Inhibition of NK and 
ADCC cytotoxicity. NK (  ) or ADCC (- - -) cytotoxicity was mea- 
sured in the presence of anti-ID (NK, 0; ADCC, i)  and NR.S (NK, 
O; ADCC, D) and expressed as percent of control. Shown are results 
representative of five normal donors with an E/T ratio of 20:1. The mean 
percent lysis was 48.7% for NK activity and 65.4% for ADCC activity. 
(B) Effect of anti-ID adsorption on cytotoxicity against K562 cells. Cyto- 
toxicity was measured in the presence of anti-ID (O); or after adsorption 
with the idiotype (Ul), (IgM[K]); or two control antibodies, an lgM()~) 
(O) and an IgM(~) (A). This graph shows results of a single representa- 
tive experiment (of three). Percent lysis _+ SE is shown using an E/T ratio 
of 20:1. 
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Figure  3.  (A)  Targeting  of lysis with  anti-ID containing hetero- 
crosslinked antibodies. LGL effector cells were pretreated with various con- 
centrations of either ID/anti-DNP (O and O) or NRS/anti-DNP (•  and 
V]) hetero-crosslinked  antibodies.  These pretreated LGL were then incubated 
with unmodified YAC cells (O and O) or with chemically  modified YAC-1 
cells (0 and i)  at an E/T ratio of 30:1 for 4 h. Percent lysis was deter- 
mined. Rabbit antibody (IgG) was used as a positive control for ADCC 
activity. (B) Reverse ADCC was determined by a 4-h SlCr release assay 
of an FcK  + NK-resistant target, Raji. LGL were pretreated with varying 
amounts of NRS (O), anti-lD (m), or anti-p104 (0). The LGL were then 
incubated with Raji cells, and the percent lysis was determined. ADCC, 
using an antibody that reacts with the target only, was used as a positive 
control. Values represent specific  lysis at an E/T ratio of 10:1. Differences 
of 5% are significantly different when analyzed using the student's paired 
t test (p 40.05). 
fragments of anti-ID,  anti-p104, or NRS, or with I1,2. Su- 
pernatants were then assayed for IFN-3, levels using a RIA. 
The ability of I1,2 (1,000 U/ml) to stimulate LGLs to secrete 
IFN-T (Table 3) was used as a positive control in each experi- 
ment. The amount of IFN-T found in supernatants of anti- 
ID-treated LGL varied among donors; however, the induc- 
tion of IFN-y by the anti-ID was dose dependent.  In both 
experiments, >0.02/~g/well (0.2 ~g/ml) of anti-ID resulted 
in the induction of detectable levels of IFN-% Higher doses 
of anti-ID induced up to 300 U/ml of IFN-% In addition, 
absorption  of the anti-ID antiserum with mAb 36 reduced 
the IFN-3, induction by >90%. The anti-p104 F(ab')2 frag- 
ments (50/~g/ml) stimulated  the LGL to secrete 45 U/ml 
of IFN-% These results demonstrated that both the anti-ID 
and anti-p104 antisera were capable of triggering the release 
of IFN-'y, in a manner similar to that previously reported 
when LGL were exposed to target cells or treated with I1,2. 
To ensure that anti-ID was not causing secretion of other 
lymphokines, levels  of I1,2 production in anti-D-treated LGL 
were also tested and no measurable secretion of I1,2 was de- 
tected (data not shown). 
Biochemical Characterization of the Anti-ID- and Anti-plO4- 
reactive Molecule(s).  Biochemical analysis of the molecule(s) 
reactive with the anti-ID antiserum was performed  using im- 
munoprecipitation and SDS-PAGE gel electrophoresis.  As 
shown in Fig. 4 A, the anti-ID immunoprecipitated an 80-kD 
molecule, a 110-kD molecule, and a 150-kD molecule from 
surface-labeled LGL under reduced (lane 2), or nonreduced 
1532  Identification of a Novel Natural Killer-binding/Trigger  Structure Table  2.  BL T-Esterase Release  frora CD3-  LGL Induced by 
Selected Antisera 
Relative units of 
Treatment  BLT-esterase released* 
LGL +  medium  ~0.5 
LGL  +  K562 (NK activity)  2.0 
LGL  +  Raji coated cells (ADCC)  20.0 
LGL  +  untreated  Raji cells  >.-0.5 
NRS (Fab')z-LGL  +  Raji  >.-0.5 
Anti-ID F(ab')z-LGL  +  Raji  10.0 
Anti-p104 F(ab')2-LGL  +  Raji  42 
Shown are results of a single representative experiment (of three). 
" Units of BLT-esterase  were  determined  after  4 h of incubation  at 37~ 
The relative units refer to the esterse activity  obtained  from 0.5  ￿  106 
LGL and calculated at an OD of 0.1. 20 U represents ~  30% of the 
total BLT-esterase  that was present in the CD3- LGL. K562 and Raji 
did not contain detectable BLT-esterase. 
Figure 4.  Biochemical  characterization  of proteins recognized  by and- 
ID and anti-p104 antisera. (.4) mI CD3- LGL surface-labeled  cell lysates 
with NRS (lane 1) or anti-ID (lane 2). (/3) 3SS-methionine  LGL cell ly- 
sates were precipitated with NRS (lane  3) or anti-p104 (lane 4). (C) nsI 
surfar.e-labeled  LGL  cell  lysates  were  immunoprecipitated  with NtLS  (lane 
5) or anti-p104 (lane  6). Gel electrophoresis  using 7.5% SDS-PAGE was 
performed under reduced  conditions  for all gels followed  by autoradiog- 
raphy. The molecular  mass  markers  used  were: myosin  (H chain),  200 kD; 
phosphorylase  13, 97.4 kD; BSA,  68 kD; OVA, 43 kD; ~ chymotrypsinogen, 
25.7 kD. 
conditions (data not shown). In contrast, immunoprecipita- 
tion of these molecules was not observed when NRS was 
used (lane I). The same proteins could not be immunopre- 
cipitated from either T  cells or monocyte membranes with 
the anti-ID antiserum (data not shown). 
The predicted amino acid sequence for the ID binding re- 
gion was delineated based on the cloning and sequencing of 
a novel gene from a human NK cell cDNA Xgtll expression 
Table  3.  Induction of IFN-T Secretion by Anti-ID Serum 
IFN-~/production 
Dose antibody 
Treatment  F(ab')2  Exp.  1"  Exp.  2*  Exp. 3* 
/zg/ral 
None  -  <2 
IL-2S  -  400 
NRS  50 
NRS  20  <2 
NRS  2  <2 
NRS  0.2  <2 
Anti-ID  20  100 
Anti-ID  2  30 
Anti-ID  0.2  5 
Anti-p104  50 
U/ml 
<2  <2 
600  800 
<2 
<2 
<2 
300 
75 
10 
45 
* In Exp. 1 and 2, the antisera was adsorbed with ID (mAb 36) and 
control IgMK (mAb35). The ID resulted in removal of >90% of the 
IFN-3' induction (<5 and 10 U/ml in Exp. 1 and 3, respectively). 
* Exp. 3 shows  the results of a single  representative  experiment (of two) 
using anti-p104. 
S  Used as positive control for IFN-'y production. 
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library (Fig. 1 A) that was identified  by the anti-ID antiserum 
(Anderson, S. K., S. Gallinger, R. Roder, J. L. Frey, H. Young, 
and J. R. Ortaldo, manuscript submitted for publication). 
A 20-amino acid sequence from the COOH end of the ID 
binding region (Fig.  1 A) was selected in an effort to obtain 
a more specific reagent that would aid in studying the rele- 
vance of the three proteins immunoprecipitated by the anti- 
ID antiserum to NK cell-mediated recognition and lysis. Since 
the anti-p104  serum exhibited similar functional reactivities 
as the anti-ID serum, biochemical analysis was performed 
in order to determine the molecular nature of the surface 
moiety that was recognized by the anti-p104 antiserum. LGL 
were either metabolically labeled or surface labeled and the 
cell lysates were immunoprecipitated with the anti-p104  an- 
tiserum. In LGL that were metabolically labeled, the anti- 
p104 antiserum immunopredpitated a 150-kD molecule (Fig. 
4 B). The recognition of the 150-kD molecule by the anti- 
p104 serum could be specifically inhibited by excess p104 (data 
not shown), and an irrelevant peptide did not inhibit the anti- 
pl04-mediated immunopredpitation (data not shown). Sev- 
eral other proteins of lower molecular masses were also im- 
munoprecipitated by anti-p104 antibodies. However, the rela- 
tionship between these proteins and their possible relevance 
to NK-mediated lysis is not yet understood. In similar ex- 
periments performed with the anti-p104  antiserum using 
surface-labeled LGL, only the 150-kD protein was immuno- 
precipitated by the anti-p104  serum (Fig.  4 C). These data 
suggest that the 150-kD protein was the functional LGL trig- 
gering molecule identified  by both the anti-ID and anti-p104 
sera. 
Discussion 
To define the molecule(s) involved in target cell recogni- 
tion by LGL, a rabbit anti-ID serum was prepared against a mAb that recognized membrane glycoproteins on the NK- 
sensitive tumor cell target, K562. The rationale for this ap- 
proach  was  that  antibodies  made  against  the  antigen- 
combining site of the mAb, which reacted with a target cell 
moiety recognized by CD3- LGL, may mimic the configu- 
ration of the molecules on CD3-  LGL that are involved in 
recognition of the target cell. Thus, the anti-ID serum should 
react with the target recognition structures on LGL. The ap- 
proach used to determine whether the anti-ID serum was 
reacting with a potential tumor recognition molecule on NK 
cells was similar to that used to identify the TCR. Specifically, 
we designed experiments to assess whether the ligand for the 
anti-ID was unique to LGL and whether the anti-ID could 
block LGbmediated binding and cytolysis. The present study 
demonstrates that the results obtained for LGL using this 
anti-ID serum parallel those criteria that were used to define 
TCR-mediated events. In particular, the anti-ID serum bound 
specifically to human CD3- LGL and blocked the ability of 
these LGL to bind to and lyse NK-sensitive  tumor targets. 
In contrast, the anti-ID did not inhibit LGl.-mediated ADCC. 
The anti-ID serum activated the lyric potential of LGL, as 
demonstrated by the ability of the antiserum to mediate re- 
verse ADCC, and when heterocross-linked, the anti-ID could 
stimulate LGL to lyse NK-resistant tumor targets.  In addi- 
tion, the recognition of a surface moiety by both the anti-ID 
and anti-p104 (an antipeptide antibody made against a pep- 
tide sequence predicted to be part of the ID binding site) 
antibodies elicited the release of BLT esterase from LGL and 
induced LGL to secrete IFN-% 
Biochemically,  the  anti-ID  serum  immunoprecipitated 
three proteins (80, 110, and 150 kD) from the surface of LGL. 
However, with the anti-ID reagent, we were not able to de- 
termine which protein(s) were relevant to NK-mediated rec- 
ognition and lysis. The possibility exists that the NK recog- 
nition/triggering molecule used by NK cells is a complex 
of proteins much like that reported for the TCR. The rela- 
tionship of these LGL proteins to each other and to LGL func- 
tion is presently under investigation. The recent cloning of 
a unique gene using this anti-ID antiserum (Anderson, S. K., 
S. Gallinger, R. Roder, J. L. Frey, H. Young, and J. R. Or- 
taldo, manuscript submitted for publication) has made pos- 
sible the development of a more specific antipeptide (anti- 
p104) serum. This reagent was demonstrated to have nearly 
identical functional reactivities as the anti-ID antiserum, but 
biochemically it recognized only the 150-kD protein on the 
surface of LGL. In addition to the 150-kD protein, other pro- 
teins of lower molecular masses were also recognized by the 
anti-p104  from metabolically labeled  LGL.  These proteins 
could represent different processed forms of the 150-kD mol- 
ecule, molecules associated with the 150-kD protein, or pro- 
teins containing a crossreactive epitope. Experiments are in 
progress to further define the relationship between the lower 
molecular mass proteins and the 150-kD protein. Therefore, 
these data are consistent with the hypothesis that the 150- 
kD protein to which the anti-ID antiserum reacts was the 
important surface ligand, which potentially has receptor func- 
tion for human CD3-  LGL NK activity.  The 80- and 110- 
kD molecules, which have different epitopes recognized by 
antibodies in the anti-ID serum not present in the anti-p104 
serum, may represent associated entities that could comprise 
an NK recognition/triggering complex. 
Several attempts have been made to determine if both the 
anti-ID and the anti-p104 recognize the same 150-kD mole- 
cule. Our most compelling evidence, though by no means 
conclusive, is based on the previously discussed biochemical 
data. Both antibodies immunoprecipitate a molecule with a 
molecular mass of 150 kD. In preliminary data, when the 
proteins are analyzed by two-dimensional gel electrophoresis, 
the 150-kD proteins immunoprecipitated  by both antisera have 
the same pI of 5.0. In further supporting the hypothesis that 
both antibodies recognize the same protein, a B-galactosidase 
fusion protein, which was produced in Escherichia coli from 
the cloned gene, was found to block the immunoprecipitation 
of the 150-kD protein by the anti-ID antisera. Furthermore, 
based on the percentages of CD56 + cells, at least 90%  of 
the ID-reactive cells are also p104 reactive. Two-color FACS  | 
analysis and crosscompetition for binding to LGL of the two 
antibodies have been performed, however, the data have been 
inconclusive. There are several explanations why these assays 
do not definitely address the issue of whether two antibodies 
are recognizing the same protein. For example, it is not pos- 
sible to distinguish by two-color analysis or erosscompeti- 
tion whether two different antibodies are recognizing  different 
epitopes of the same molecule, whether they are recognizing 
two different molecules, or whether the binding of one anti- 
body may be sterically interfering with the binding of the 
second antibody. Therefore, the most definitive proof that 
both antibodies are recognizing the same molecule is to ana- 
lyze the amino acid sequence of the 150-kD protein immu- 
noprecipitated by  each  antibody.  These  experiments  are 
presently underway in our laboratory. 
Based on the predicted amino acid sequence, the surface 
moiety recognized by the anti-ID antiserum has been shown 
to be different from the immunoglobulin supergene family 
and the integrin supergene family. This molecule contains 
several distinct structural features,  including a cyclophilin- 
like domain, three positively charged domains, serial histone  ~ 
like domains, and several serine-rich domains. However, there 
is no homology with serine or tyrosine kinases or with pro: 
tein phosphatases (Anderson, S. K., S. Gallinger, R. Roder, 
J. L. Frey, H. Young, and J. R. Ortaldo, manuscript sub- 
mitted for publication). Because of the unique structure of 
this molecule and our finding that it plays an important role 
in the recognition and lysis of tumor cell by NK cells, this 
molecule may represent a novel class of receptors. 
Several investigators have reported the development of mAbs 
that recognize surface molecules on fish LGL (37), rat LGL, 
and lymphokine-activated killer (LAK) cells (38), or human 
LGL (39, 40) and LAK cells (40). These molecules have been 
proposed to be involved in the activation and regulation of 
NK activity. However, none of these molecules are associated 
exclusively with NK activity. In contrast, preliminary studies 
of the p150 molecule we have identified demonstrated its ex- 
pression on the cell surface of Ib2-activated lymphocytes by 
FACS  |  analysis, but no ability of the anti-ID serum to in- 
hibit IL-2-activated killing (data not shown). This suggested 
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important in target recognition and lysis by unstimulated NK 
cells, but that LAK cells recognized and/or lysed targets differ- 
ently. This observation may partially explain the broader target 
cell spectrum for LAK-mediated cytolysis (41).  Thus,  since 
the anti-ID  serum did not appreciably inhibit  either LAK 
activity or ADCC, the ligand for the anti-ID appears to be 
a receptor specifically related to the mechanism  of NK ac- 
tivity. Thus, the relationship between the 150-kD molecule 
(and the 110- and 80-kD molecules) identified in our studies 
and the proteins reported elsewhere remains unclear.  None 
of the previously reported molecules (37-40) correlate with 
respect to size, function, and cellular distribution to the p150 
molecule reported herein.  To define whether a molecule is 
a true NK recognition receptor will require additional con- 
firmation either by transfection of a full-length gene into cells 
lacking NK activity or by abrogation of expression of the 
proposed receptor in NK cell lines or clones with antisense 
cDNA vectors. However, based on the novelty of the gene 
that was cloned using the anti-ID antiserum, and the ability 
of this molecule to mediate reverse ADCC, trigger LGL to 
release BLT esterase, and induce LGL to secrete IFN-% when 
stimulated by the anti-ID or anti-p104,  the 150-kD protein 
appears to represent an important  molecule involved in the 
triggering  of NK-mediated lytic function.  Current  studies 
are underway in our laboratories to determine if the 150-kD 
protein represents a biologically relevant NK cell recognition/ 
triggering  receptor. 
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